

Conference Cochairs:

Olivier Delattre, Inserm/Institut Curie, Paris, France
Annie A. Huang, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
David M. Langenau, Mass General Brigham, Boston, MA
Suzanne P. MacFarland, Children's Hospital of Philadelphia, Philadelphia, PA

Tuesday, September 22, 2026

Opening Plenary Session

Grand Ballroom A-C

4:45-7:00 p.m. |

- | | |
|------------|--|
| 4:45- 5:00 | Welcome and Introduction |
| 5:00-5:50 | Keynote : Toward a cure of acute leukemia through the lens of genomics
Charles Mullighan, St. Jude's Children's Hospital, Memphis, Tennessee |
| 5:50-6:00 | Discussion/Q&A |
| 6:00-6:50 | AACR-St. Baldrick's Foundation Pediatric Cancer Research Fellowship Awardee Lecture
Understanding and targeting NUP98 fusion oncoprotein condensates
Nicole Michmerhuizen, University of Rochester Medical Center, Rochester, New York |
| 6:50-7:00 | Discussion/Q&A |

Opening Reception and Poster Session A

Grand Ballroom D

7:00-8:30 p.m. |

Wednesday, September 23, 2026

Continental Breakfast

7:00-8:00 a.m. |

Plenary Session 1: Cell States, Plasticity, and Metastatic Progression

8:00-10:00 a.m.

Session Chair: David Langenau

- | | |
|------------|--|
| 8:00- 8:05 | Session Chair Introduction |
| 8:05-8:35 | Cell state heterogeneity and therapy resistance in rhabdomyosarcoma
David M. Langenau, Mass General Brigham, Boston, Massachusetts |

- 8:35-9:05 **Single-cell regulatory network analysis of cell state heterogeneity and remodeling under therapy to design treatment strategies in osteosarcoma**
Jovana Pavisic, Memorial Sloan Kettering Cancer Center, New York, New York
- 9:05-9:35 **Metabolic flexibility at the crux of aggressive behavior in Ewing sarcoma**
Poul Sorensen, University of British Columbia, Vancouver, British Columbia, Canada
- 9:35-9:50 **Immunocompetent models reveal lineage state-specific immune escape mechanisms in neuroblastoma***
Adam J. Wolpaw, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- 9:50- 10:05 **A genome-derived non-coding cell state reporter guides therapeutic strategies for transcriptional reprogramming in neuroblastoma***
Noha Shendy, St. Jude's Children's Hospital, Memphis, Tennessee

Break

10:05- 10:25 a.m. |

CHAIR GIFT CEREMONY

Plenary Session 2: Emerging Mechanisms and Therapeutic Vulnerabilities

10:35 a.m.-12:15 p.m. |

Session Chair: Annie Huang

- 10:35- 10:40 **Session Chair Introduction**
- 10:40-11:10 **Strategies to Eliminate Drug-Tolerant Neuroblastoma Persister Cells**
John Maris, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- 11:10-11:40 **New insights into mechanisms of oncogenic miRNAs**
Annie A. Huang, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
- 11:40- 11:55 **NF1 loss disrupts a SMARCA2–CTCF–H1 chromatin-remodelling axis and creates DNA repair vulnerability in retinoic acid-resistant high-risk neuroblastoma**
Sally George, Institute of Cancer Research, London, United Kingdom
- 11:55- 12:10 **Characterization of patient-specific CHEK2 genetic variants in high-risk neuroblastoma***
Xueting Xiong, University of Toronto, Toronto, Ontario, Canada

12:10- 12:25 **Investigating mechanisms of resistance in Philadelphia chromosome-like acute lymphoblastic leukemia***

Thai Hoa Tran, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada

Lunch Break (lunch on your own)

12:25-2:25 p.m.

Plenary Session 3: Developmental Pathways in Pediatric Cancer

2:25 -4:30 p.m. |

Session Chair: James Amatruda

2:25- 2:30 **Session Shair Introduction**

2:30-3:00 **Identity theft: origins of rhabdomyosarcoma**

Mark Hatley, St. Jude's Children's Hospital, Memphis, Tennessee

3:00-3:30 **Cell fate and lineage plasticity in the development of Ewing sarcoma**

James Amatruda, Children's Hospital of Los Angeles, Los Angeles, California

3:30-4:00 **Dissecting the differentiation block in Fusion-driven AMKL**

Kim Stegmaier, Dana Farber Cancer Institute, Boston, Massachusetts

4:00-4:15 **Activated ALK and MYCN drive neuroblastoma initiation through tissue-specific dynamics of neuroblast persistence and transformation***

Isabelle Janoueix-Lerosey, Inserm/Institut Curie, Paris, France

4:15- 4:30 **Overcoming drug resistance in Sonic hedgehog-driven medulloblastoma***

Rodney Stewart, Huntsman Cancer Institute, Salt Lake City, Utah

Plenary Session 4: Early-Career Investigator Perspectives Across the Pediatric Oncology Landscape

4:30 -6:35 p.m. |

Session Chair: Meredith Irwin

4:30- 4:35 **Session Shair Introduction**

4:35- 4:40 **Pediatric Cancer Working Group Social Media talk**

4:40- 5:10 **Immune Related Toxicities of CART**

Caroline Diorio, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

5:10-5:40 **From acute adaptation to durable response in pediatric rhabdomyosarcoma**

Anand Patel, St. Jude's Children's Hospital, Memphis, Tennessee

5:40- 6:10 **Identifying and targeting tumorigenic signals in the developing liver**

Peng V. Wu, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

6:10- 6:40 **Supportive Care/ Survivorship**

Katie A. Greenzang, Dana Farber Cancer Institute/ Boston Children's Hospital,
Boston, Massachusetts

Poster Session B (with light refreshments)

7:00- 9:00 p.m. |

Thursday, September 24, 2026

Continental Breakfast

7:00-8:00 a.m. |

Plenary Session 5: Tumor Microenvironment and Immunity

8:00- 9:50 a.m. |

Session Chair: Catherine Bollard

8:00- 8:05 **Session Chair Introduction**

8:05-8:35 **Marking and modulating microenvironmental reprogramming in pediatric cancer progression**

Rosandra Kaplan, National Cancer Institute, Bethesda, Maryland

8:35-9:05 **Enhancing tumor associated antigen-specific T cell responses for pediatric cancer**

Catherine Bollard, Children's National Research Institute, Washington D.C

9:05-9:20 **Oligodendrocyte-secreted factor L-PGDS potentiates phagocytosis of tumor-associated myeloid cells in pediatric high-grade gliomas***

Kevin Hu, The University of Houston, Houston, Texas

9:20- 9:35 **Using omics technologies to understand hepatoblastoma heterogeneity and identify tumor cell types and their microenvironment for precision medicine***

Elise Lelou, University of San Francisco, San Francisco, California

9:35- 9:50 **Elucidating epigenetic regulators of GD2 in Ewing sarcoma***

Xiaochen Zhang, Purdue University, West Lafayette, Indiana

Break

9:50-10:20 a.m. |

Plenary Session 6: Advances in Immunotherapy for Pediatric Cancer

10:25 a.m.-12:30 p.m. |

Session Chair: Terry Fry

- | | |
|--------------|---|
| 10:25- 10:30 | Session Chair Introduction |
| 10:30-11:00 | GD2-CAR T cells for H3K27M DMGs: Status Update
Crystal Mackall, Stanford University, Stanford, California |
| 11:00-11:30 | Addressing challenges with CAR T cells for AML
Terry Fry, Children's Hospital Colorado Anschutz, Aurora, Colorado |
| 11:30-11:45 | Real-world efficacy of immune checkpoint inhibitors when used in a selected population of pediatric solid cancers – A retrospective multicenter study*
Andy Huy-Dat Vu, Centre Hospitalier Universitaire de Québec, Laval University, Quebec City, Quebec, Canada |
| 11:45-12:00 | Unveiling the immunoregulatory role of tumoral B7-H3 in promoting the immunosuppressive TME of medulloblastoma*
Kirsten Moziak, Albert Einstein College of Medicine, New York, New York |

Lunch Break (lunch on your own)

12:00-2:00 p.m. |

Plenary Session 7: Tumor Genomics, Predisposition, and Mosaicism

2:00-4:20 p.m. |

Session Chair: Suzanne MacFarland

- | | |
|------------|-----------------------------------|
| 2:00- 2:05 | Session Chair Introduction |
|------------|-----------------------------------|

- 2:05-2:35 **New frontiers in childhood cancer predisposition: Harnessing genomics for early detection and tumor interception**
David Malkin, SickKids, Toronto, Ontario, Canada
- 2:35-3:05 **Defining phenotype and polyp development in Juvenile Polyposis Syndrome**
Suzanne P. MacFarland, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- 3:05-3:35 **The germline-somatic dialogue in Ewing sarcoma susceptibility**
Olivier Delattre, Inserm/Institut Curie, Paris, France
- 3:35-3:50 **Childhood cancer data initiative's research characterization data reveals novel biology***
Emily Boja, National Institute of Health, Bethesda, Maryland
- 3:50- 4:05 **Male Y chromosome loss as a candidate driver in high-risk neuroblastoma***
Esther Rheinbay, Mass General Brigham, Boston, Massachusetts
- 4:05- 4:20 **Zebrafish cancer models predict clinical outcomes in human acute lymphoblastic leukemia***
Mohamed Bakr, Mass General Brigham, Boston, Massachusetts

Accelerating Breakthroughs Together: An Industry Perspective on Collaboration: Panel Discussion
4:20-5:20 p.m. |

Panelists: Joe McDonough, The Andrew McDonough B+ (Be Positive) Foundation, Wilmington, Delaware
Adam S. Levy, Bristol Myers Squibb, Jericho, New York
Kerri Nottage, Johnson & Johnson, Flemington, New Jersey
Devona Williams, AstraZeneca, Washington, District of Columbia

Poster Session C (with light refreshments)
5:30- 7:30 p.m. |

Friday, September 25, 2026

Continental Breakfast
7:00-8:00 a.m. |

Plenary Session 8: Cancer Cell Biology, Organelle Function, and Metabolism



8:00-10:00 a.m. |

Session Chair: Olivier Delattre

- | | |
|-------------|---|
| 8:00- 8:05 | Session Chair Introduction |
| 8:05-8:35 | New insights into drug resistance
Alejandro Gutierrez, St. Jude's Children's Hospital, Memphis, Tennessee |
| 8:35-9:05 | Chromatin regulation by EWS fusion proteins
Miguel N. Rivera, Mass General Brigham, Boston, Massachusetts |
| 9:05-9:35 | Multi-omic integration and lipid dependency in Medulloblastoma
Olivier Ayrault, Institut Curie, Paris, France |
| 9:35-9:50 | Revealing a novel role for YB-1 as metabolic regulator in Ewing sarcoma*
Annalena F. Renner, BC Cancer Research Center, Vancouver, British Columbia, Canada |
| 9:50- 10:05 | Multi-omic profiling reveals endothelial cell plasticity in metastatic osteosarcoma*
Troy A. McEachron, National Cancer Institute, Bethesda, Maryland |

Break

10:05-10:30 a.m. |

Plenary Session 9: Transformative Technologies for Clinical Care

10:30 a.m.-12:20 p.m. |

Session Chair: Brian Crompton

- | | |
|--------------|--|
| 10:30- 10:35 | Session Chair Introduction |
| 10:35-11:05 | Advancing liquid biopsies for the clinic and discovery in Pediatric Cancer
Brian Crompton, Dana-Farber Cancer Institute, Boston, Massachusetts |



11:05-11:35 Overcoming Heterogeneity: Deep Learning for Automated Subtyping of Pediatric Sarcomas

Jill Rubinstein, The Jackson Laboratory, Farmington, Connecticut

11:35-11:50 Advancing a comprehensive pediatric liquid biopsy platform, LBSeq4Kids, using Illumina 5-Base technology*

Laura A. T. Kagami, Children's Hospital of Los Angeles, Los Angeles, California

11:50- 12:05 Tumor-free RB1 molecular diagnosis: Aqueous humor liquid biopsy enables comprehensive in vivo characterization of biallelic rb1 inactivation in retinoblastoma*

Liya Xu, Children's Hospital of Los Angeles, Los Angeles, California

12:05- 12:20 Robust identification of recurrent gene expression programs across samples from the Single-cell Pediatric Cancer Atlas Portal*

Allegra G. Hawkins, Alex's Lemonade Stand Foundation, Bala Cynwyd, Pennsylvania

Closing Remarks

12:20-12:35 p.m. |